MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze SMMT →
    • FindStock Picks / Stock Screener
    • Value · SMMTIntrinsic Value Calculator
    • Invest · SMMTInvestment Case
    • Hold · SMMT5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SMMT stock logo

SMMT

Summit Therapeutics Inc.

$14.15
-0.93
 (-6.14%)
Exchange:  NASDAQ
Market Cap:  11.288B
Shares Outstanding:  747.7M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Robert W. Duggan
Full Time Employees:  265
Address: 
601 Brickell Key Drive
Miami
FL
33131
US
Website:  https://www.smmttx.com
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company’s clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
SMSMMT logoSMMTSummit Therapeutics Inc.11.3B——-145.8%
HAHALO logoHALOHalozyme Therapeutics, Inc.11.4B23.911.622.6%
TETECH logoTECHBio-Techne Corporation11.4B66.237.97.3%
BMBMRN logoBMRNBioMarin Pharmaceutical Inc.11.1B—13.7-1.0%
KYKYMR logoKYMRKymera Therapeutics, Inc.10.9B——-23.9%
PCPCVX logoPCVXVaxcyte, Inc.10.0B——-45.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/07/23 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit000
EBITDA-88,483-210,879-1,079,390
Operating Income-609,650-225,997-1,094,374
Net Income-614,928-221,315-1,079,586

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets202,949435,560751,182
Total Liabilities125,25746,81292,322
Total Stockholders Equity77,692388,748658,860
Total Debt106,0997,21820,890
Cash and Cash Equivalents71,425104,862225,266

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-76,760-142,106-322,930
Capital Expenditure-128-139-657
Free Cash Flow-76,888-142,245-323,587
Net Income-614,928-221,315-1,079,586
Net Change in Cash-577,18233,762120,395

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)609,342.171Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)11,485,433.807Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)3,948,169Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)137,701.053Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)5,371,862.754Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)1,723,266.575Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-115,407.495Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)4,043,815.823Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,161,424.842Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)6,579,103.462Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)124,008,908.162Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)42,628,614.222Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.550Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)5.410Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.150Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-221.315M  ?P/E
 (TTM)
: 
-13.22
?Enterprise Value
 (TTM)
: 
11.157B  ?EV/FCF
 (TTM)
: 
-21.16
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-138.81%  ?ROIC
 (TTM)
: 
-145.82%
?Net Debt
 (TTM)
: 
-405.456M  ?Debt/Equity
 (TTM)
: 
0.04
?P/B
 (TTM)
: 
20  ?Current Ratio
 (TTM)
: 
5.99

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates SMMT intrinsic value between $1.27 – $2.79 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SMMT Intrinsic Value

Common questions about SMMT valuation

Is Summit Therapeutics Inc. (SMMT) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Summit Therapeutics Inc. (SMMT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SMMT a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SMMT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SMMT’s P/E ratio?

You can see SMMT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SMMT?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SMMT a good long-term investment?

Whether SMMT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Summit Therapeutics Inc.

  • Summit Therapeutics Inc. intrinsic value calculatorEstimate what the business is worth
  • Summit Therapeutics Inc. 5-year outlookWhat has to go right, and what could go wrong
SMMT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-6.14
MarketSnap

Trading Metrics:

Open: 15.2   Previous Close: 15.08
Day Low: 14.06   Day High: 15.2
Year Low: 12.07   Year High: 29.23
Price Avg 50: 16.47   Price Avg 200: 16.15
Volume: 5.492M   Average Volume: 5.524M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
04-11-2026 16:36
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
23-10-2026 21:26
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
23-10-2026 16:37
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
22-10-2026 06:00
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
21-10-2026 06:05
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
02-10-2026 03:00
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze SMMT →
    • FindStock Picks / Stock Screener
    • Value · SMMTIntrinsic Value Calculator
    • Invest · SMMTInvestment Case
    • Hold · SMMT5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.